Building Your First 90-Day Protocol
Ninety days is the minimum viable data window for a peptide protocol. Short enough to remain manageable. Long enough to produce meaningful signal. This module assembles everything from the previous four modules into a structured, phase-by-phase execution plan.
Why Three Phases Exist
A structured protocol is not three months of doing the same thing every day. It is three distinct phases, each with a specific purpose and a defined endpoint. The phase structure exists for one reason above all others: single-variable data integrity.
If you change multiple variables simultaneously, you cannot attribute outcomes to specific causes. Phase 1 establishes your baseline response to the stack at conservative doses. Phase 2 optimizes within the stack based on what Phase 1 revealed. Phase 3 consolidates and collects clean data for the week 10 lab recheck. The phases create the structure within which your data becomes interpretable.
A protocol is a controlled experiment. The three-phase structure is the experimental design. Remove the phases and you have a series of events. Keep the phases and you have a dataset you can learn from and hand forward to the next protocol cycle.
Phase 1: Calibration
Phase 1 is the lowest dose, highest structure phase of the protocol. Every compound runs at the conservative end of the beginner reference range. Timing adherence is strict. Tracking begins on Day 1. The purpose is not to produce maximum effect. The purpose is to establish your individual response baseline with minimal noise variables.
BPC-157 runs at 250 mcg once daily, morning administration. TB-500 runs at 5mg once weekly. Ipamorelin runs at 200 mcg once daily, pre-sleep fasted. These are the entry doses. They are not conservative because they are ineffective: they are conservative because they let the biology speak clearly without dose-level noise confounding the signal.
Week 3 is the first checkpoint. Before advancing to Phase 2, each checkpoint criterion must be satisfied. If any criterion is not met, Phase 1 extends until it is.
Phase 1 Checkpoint Criteria
Phase 2: Optimization
Phase 2 is where the data from Phase 1 drives protocol adjustment. By the end of three weeks, you have meaningful subjective data on sleep quality, recovery, any tissue-specific changes, and energy patterns. Phase 2 uses that data to optimize within the established framework.
Common Phase 2 adjustments: BPC-157 moves to 500 mcg if no notable response was observed at 250 mcg and there are no adverse signals. Ipamorelin optionally adds a second daily dose (morning, fasted) if the evening dose is producing strong sleep quality improvement but the optimization target also includes body composition. TB-500 holds at 5mg weekly through Week 6, then drops to 5mg bi-weekly (every two weeks) for the maintenance phase of loading.
One adjustment at a time. One week of observation before the next adjustment. This is the discipline that makes Phase 2 data readable. Each change must be isolated to a single variable so that changes in subjective markers can be attributed to the specific adjustment.
What to Measure and How Often
Tracking in Phase 2 requires more granularity than Phase 1 because you are actively making adjustments and need to capture the response to each one. The tracking categories are:
| Category | Metric | Frequency |
|---|---|---|
| Sleep quality | Sleep depth, wakefulness episodes, HRV if tracked | Daily |
| Recovery | DOMS duration after training, subjective fatigue rating 1-10 | Daily |
| Tissue-specific | Pain levels for any targeted injury site (0-10 scale) | Daily |
| Body composition | Weekly photos (same lighting, same time), waist measurement | Weekly |
| Energy and cognition | Subjective energy rating 1-10, notable cognitive events | Daily |
| Compliance | Dose administered, time, fasted status for Ipamorelin | Per dose |
Phase 3: Consolidation
Phase 3 holds the optimized Phase 2 doses constant. No further adjustments. This phase serves as the clean control period from which the week 10 lab results can be interpreted. If doses and timing are still shifting in week 10, the lab results reflect a moving target. Phase 3 ensures the biology is operating at a steady state when the blood draw happens.
The week 10 lab draw should happen on a day that is representative of the protocol: typical sleep the night before, typical fasting window, not following unusually intense training, not during a period of illness or unusual stress. Anomalous context produces anomalous results. Mark the lab draw conditions in the tracking log.
Phase 3 also includes the retrospective review: reading back through the full tracking log to identify patterns that were not visible week-to-week. When did sleep quality peak? At what week did the tissue-specific pain metric drop below 4? Was there a timing correlation between any protocol adjustment and a subjective change? This review builds the intelligence that informs the next protocol design.
The Daily Schedule
Adjusting When Results Are Not Appearing at Week 6
Week 6 is the mid-protocol diagnostic checkpoint. By this point, you have six weeks of tracking data. If subjective markers have not shown any directional change from baseline across any category, a structured diagnostic review is warranted before adjusting doses. The cause of non-response is almost always one of four things:
Compliance gaps. Review the tracking log honestly. How many Ipamorelin doses were administered in a fed state? How many BPC-157 doses were missed? Even 3-4 compliance failures per week over six weeks can blunt the signal significantly. If the log reveals compliance issues, correct them before changing doses.
Poor reconstitution. If the peptide was degraded during reconstitution, you have been administering a partially or fully inactive compound for six weeks. If there is any doubt about reconstitution quality, prepare fresh vials using the Module 3 protocol precisely, confirm concentration calculations, and restart Phase 1.
Below-threshold baseline. Some individuals with very low IGF-1 at baseline, very low testosterone, or elevated chronic CRP require a longer calibration period before subjective response appears. The biology is real and active, but the noise floor from pre-existing deficiencies is higher. Review the baseline lab context before concluding non-response.
Dose at lower end for body composition. For individuals with significantly higher lean mass or body weight, Phase 1 conservative doses may be producing sub-threshold tissue concentrations. If compliance is confirmed clean and reconstitution is verified, a structured dose increase is appropriate. Move one compound at a time, one week of observation per adjustment.
What "Complete" Looks Like at Day 90
Day 90 completion is not just the end of the injection schedule. It is the completion of a specific dataset. A complete 90-day protocol produces the following outputs:
A full tracking log covering all 90 days, with consistent daily entries across all required fields. No more than 5% missing data days across the protocol. A baseline lab panel and a week 10 lab panel, both with results recorded and compared. A written protocol retrospective answering: What changed? When did it change? What drove the change? What would I adjust for the next cycle? A day 90 lab draw date scheduled for the final lab comparison point.
The day 90 data package is the asset you carry into Unit 2. Your baseline, your response curve, your compliance record, your lab trajectory. This data makes every subsequent protocol more precise than a first protocol could ever be. The 90 days are not just optimization. They are the construction of a personalized biological reference dataset.
What Day 90 Data Enables Next
A completed 90-day beginner stack produces three specific capabilities that were not available at day zero. First, you know how your IGF-1 axis responds to Ipamorelin at a specific dose and timing. This tells you whether the GH secretagogue is effective and whether the dose is appropriately sized for your biology. This data is the foundation for Module 6, which covers more advanced GH secretagogue comparisons.
Second, you have a CRP and fasting insulin trajectory that tells you whether the anti-inflammatory mechanisms of the stack (BPC-157, TB-500) produced measurable systemic effect in your specific inflammatory context. If CRP remained elevated despite protocol compliance, the data points toward either a higher-dose or longer-duration protocol cycle, or toward adding a more targeted anti-inflammatory compound in the next cycle.
Third, you have a subjective response map: which domains responded first, which responded most strongly, which showed no response. This map is the starting point for designing a more targeted next protocol rather than defaulting to the same beginner stack indefinitely.
The Mindset Framework: Patience as a Protocol Variable
The most common reason a first protocol fails to produce usable data is not dose error or reconstitution failure. It is premature abandonment driven by the expectation of faster results than biology allows.
Biological adaptation operates on timescales measured in weeks, not days. VEGF-driven angiogenesis requires time for new vessel development. IGF-1 stabilization at a new setpoint requires 6-8 weeks of consistent secretagogue stimulation. Collagen remodeling in tendon tissue takes 6-12 weeks of sustained biological signal before structural change is measurable.
The 90-day structure is not arbitrary. It is the minimum window within which the biology can produce measurable, meaningful change. A protocol abandoned at week 4 because results are not yet visible is a protocol that was abandoned before the biology had sufficient time to respond. Week 6 is typically when the first clear subjective signals appear. Week 10 is when objective lab changes become statistically meaningful.
Patience within a protocol is not passive. It is active: tracking daily, adhering to timing, maintaining compliance records, building the data set. The patience is in not changing variables before you have the data to justify the change. That discipline is what separates a protocol that produces usable intelligence from an experiment that produces noise.
THE PIVOTAL PROTOCOL presents this protocol structure as educational material only. The specific phases, doses, and schedules described are reference frameworks for educational purposes and do not constitute medical advice or a prescription for self-administration. Individual protocol design should be supervised by a qualified physician. All clinical decisions must remain with a licensed healthcare provider.
- The three-phase structure (Calibration, Optimization, Consolidation) exists to maintain single-variable data integrity. Each phase has a defined purpose, and checkpoint criteria must be met before advancing.
- Phase 1 conservative doses are not a compromise. They establish a clean baseline response that makes Phase 2 adjustments interpretable. A protocol that starts at maximum dose has nowhere to go and no comparison point.
- Week 6 is the mid-protocol diagnostic checkpoint. Non-response at week 6 triggers a structured compliance and reconstitution review before any dose adjustment.
- Day 90 completion produces a specific data package: full tracking log, two-point lab comparison, and a written retrospective. This package is the asset that makes the next protocol more precise than the first.
- Patience is a protocol variable with measurable consequences. Premature abandonment is the most common source of failed first protocols. Biological timescales require weeks, not days, for meaningful measurable change.
- The data from day 90 enables more targeted protocol design for cycle two: known IGF-1 axis response, inflammatory marker trajectory, and a subjective response map across all tracked domains.